Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash Flows from Operating Activities
Net income	$ 232	$ 396
Adjustments to reconcile net income to net cash flows provided by operating activities:
Depreciation	70	64
Amortization	103	67
Impairment of assets	9	0
Acquired in-process research and development and milestones	6	30
Accretion and changes in fair value in contingent consideration	23	0
Deferred income tax (benefit) expense	(7)	26
Stock-based compensation	46	54
Unrealized foreign exchange loss (gain)	1	(20)
Gain on debt repurchase	(46)	0
Other	44	14
Net changes in assets and liabilities, net of assets acquired
Accounts receivable	(76)	88
Inventories	(31)	(39)
Other current assets	(78)	(156)
Trade accounts payable	(109)	(56)
Accrued and other current liabilities	(59)	(92)
Income taxes payable	46	2
Other	121	30
Net Cash Flows Provided by Operating Activities	295	408
Cash Flows from Investing Activities
Capital expenditures	(71)	(78)
Proceeds from sale of property, plant and equipment	1	1
Acquired in-process research and development and milestones	(10)	(15)
Dermavant acquisition, net of cash acquired	(75)	0
Purchase of product rights and asset acquisition	(55)	(50)
Net Cash Flows Used in Investing Activities	(210)	(142)
Cash Flows from Financing Activities
Proceeds from debt	430	1,036
Repayments of debt	(634)	(1,043)
Payment of long-term debt issuance costs	0	(36)
Employee withholding taxes related to stock-based awards	(13)	(16)
Dividend payments	(81)	(149)
Net Cash Flows Used in Financing Activities	(298)	(208)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	137	(47)
Net (Decrease) Increase in Cash and Cash Equivalents	(76)	11
Cash and Cash Equivalents, Beginning of Period	675	693
Cash and Cash Equivalents, End of Period	$ 599	$ 704